July 25th 2024
ConSynance Therapeutics' CSTI-500, an innovative Triple Monoamine Reuptake Inhibitor, has received FDA's Rare Pediatric Disease Designation for treating Prader-Willi Syndrome in children.
Tackling Inequities in IBD: Inclusive Solutions for Elevated Patient Care
October 26, 2024
Register Now!
Clinical Consultations™: Managing Depressive Episodes in Patients with Bipolar Disorder Type II
View More
Medical Crossfire®: Understanding the Advances in Bipolar Disease Treatment—A Comprehensive Look at Treatment Selection Strategies
View More
'REEL’ Time Patient Counseling: The Diagnostic and Treatment Journey for Patients With Bipolar Disorder Type II – From Primary to Specialty Care
View More
Clinical ShowCase™: Finding the Best Path Forward for Patients with COPD
View More
Surv.AI Says™: What Clinicians and Patients Are Saying About Glucose Management in the Technology Age
View More
A Tethered Approach to Type 2 Diabetes Care – Connecting Insulin Regimens with Digital Technology
View More
First patient treated in adolescent epilepsy trial assessing NeuroPace RNS system
May 17th 2022Since its approval for the treatment of medical refractory epilepsy in 2013, the closed-loop neuromodulation device has had its efficacy and safety confirmed in several pivotal studies and will now be assessed in focal epilepsy in the RESPONSE trial.
Is there room for improvement in neuroimage use in suspected abuse cases in infants?
April 28th 2022When an infant presents with fractures that suggest possible abuse, but appears to be neurologically fine, clinicians should make sure to rule out occult head injury. A report looks at whether many children’s hospitals are routinely following this guidance.
Managing headache with a tiered approach
October 3rd 2020Headache may be one of the most recognizable health concerns, but managing it may not always be clear. A presentation at the virtual 2020 American Academy of Pediatrics National Conference & Exhibition offers a tiered approach to aid in management.